Occam Recruits Laurent Fischer as Chair of Shinobi Therapeutics
In November 2025, Occam Global, a leader in executive recruiting for the life sciences, placed Laurent Fischer, MD, as the first independent Chairman of the Board of Directors of Shinobi Therapeutics.
Fischer brings over 30 years of senior leadership experience in biotechnology to Shinobi, with a proven track record of building, growing, and exiting companies focused on innovative therapies. His achievements include selling Jennerex Biotherapeutics to SillaJen, leading Tobira Therapeutics through its IPO and its $1.7 billion acquisition by Allergan, chairing CTI BioPharma during the approval and launch of Vonjo™, and its subsequent $1.7 billion sale to SOBI, and most recently, selling Adverum Biotechnologies to Eli Lilly in October 2025.
Fischer also brings extensive board experience, including current positions as the first independent Director of Lycia Therapeutics, Director of Mirum Pharmaceuticals, and Director of AtaiBeckley. He previously served as Chair of Tobira Therapeutics, Chairman of CTI BioPharma, Director of Senti Biosciences, and Senior Advisor of Frazier Healthcare Partners.
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.